TRC160334 is a hydroxylase inhibitor of hypoxia-inducible factor (HIF). It is employed in research about ischemia/reperfusion injury.

TRC160334 treatment (100~400 μM; 4 hours; Hep3B cells) leads to dose-dependent stabilization and transcriptional activation of nuclear HIF-1, as evidenced by Western Blot Analysis. Additionally, TRC160334 at concentrations ranging from 75~300 μM for 4 hours in Hep3B cells induces dose-dependent expression of HIF-targeted genes, such as EPO and adrenomedullin, showcasing its impact on cellular responses through HIF-1 pathway modulation.

In studies with Sprague-Dawley male rats (250–300 g), TRC160334 at doses of 0.1 and 0.3 mg/kg administered intraperitoneally (i.p.) notably lowered serum creatinine and blood urea nitrogen, indicative of renal function improvement. When the dosage was increased to 0.3 and 0.6 mg/kg (i.p.), TRC160334 demonstrated a tendency to mitigate acute tubular necrosis. Moreover, the compound effectively moderated dose-dependent increases in electrolyte excretion. Interestingly, pre-ischemic treatment with TRC160334 led to a significant elevation of HSP70 in kidneys within 6 hours, whereas post-ischemic treatment achieved a similar induction by 12 hours, compared to control groups. These findings suggest TRC160334's potential in protecting against kidney damage and promoting renal recovery.